Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Liver Transplant Recipients
Observational
Observational Model: Cohort, Time Perspective: Prospective
Acute Rejection
The primary endpoint is the incidence of biopsy proven AR at 3, 12 and 24 months after LT.
3 months after liver transplant
Yes
Josh Levitsky, MD, MS
Study Chair
Northwestern Univ.
United States: Federal Government
DAIT CTOT-14
NCT01672164
August 2012
August 2015
Name | Location |
---|---|
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
Medical University of South Carolina | Charleston, South Carolina 29425-0721 |
Baylor University Medical Center | Dallas, Texas 75246 |
Mayo Clinic | Scottsdale, Arizona |
Northwestern University, Feinberg School of Medicine | Chicago, Illinois 60611 |
Scripps Center for Organ and Cell Transplantation | La Jolla, California 92037 |